摘要
目的探讨血清人附睾上皮分泌蛋白4(HE4)、CA125和卵巢恶性肿瘤风险模型(ROMA)对女性卵巢癌疾病的诊断应用价值。方法选择经石蜡切片病理报告确诊的患者:卵巢癌患者64例(A组)、卵巢良性疾病120例(B组)、健康女性对照者38例(C组)。比较各组HE4、CA125水平,结合绝经状态,根据ROMA结果预测卵巢恶性肿瘤的发病情况。血清HE4、CA125水平检测使用酶联免疫吸附法和微粒子化学发光法。结果卵巢癌组血清HE4、CA125水平和ROMA值高于健康对照组(P<0.05),盆腔良性疾病组血清CA125水平和ROMA值高于健康对照组(P<0.05),盆腔良性疾病组HE4水平与健康对照组差异无统计学意义(P>0.05)。HE4、CA125和ROMA值的特异性分别为98.33%、80.80%、82.50%;敏感性分别为75.00%、65.62%、81.25%,HE4特异性最好,ROMA值敏感性最好。HE4的阳性率还与患者年龄显著相关,ROMA指数的阳性率则与患者年龄、绝经状态显著相关(P<0.05)。结论血清HE4、CA125的联合检测及ROMA指数的计算有助于评估腹盆腔肿块患者患卵巢癌的风险情况。
Objective To explore the diagnosis value of combined serum human epididymis protein 4 (HFA), carbohydrate antigen CA125 with ROMA index in ovarian cancer. Methods The patients with ovarian cancer were diagnosed confirmed by histological examination from biopsy. Sixty - four cases of ovarian cancer ( A group) and 120 cases of benign ovarian disease( B group) were selected. And 38 healthy subjects were selected as control group( C group). The difference in HFA, CA125 between the groups were analyzed, combine with with menopause status;based on the value of ROMA index predicted the incidence of ovarian cancer. HFA and CA125 were detected by enzyme - linked immunoassay (ELISA) and chemiluminescence. Results The serum levels of HFA,CA125 and ROMA in patients with ovarian cancer were significantly higher than those in controls (P 〈 0. 05 ). The serum levels of CA125 and ROMA in patients with benign ovarian disease were significantly higher than those in healthy subjects (P 〈 0.05 ). The serum HFA between benign ovarian disease group and control group was not statistically significant ( P 〉 0.05 ). The Specificity and sensitivity of HFA,CA125,ROMA were 98. 33% ,80.80% ,82.50% and 75.00% ,65.62% ,81.25% ,respectively. The specificity of HFA was best, the sensitivity of ROMA was best. The positive rate of serum HFA was associated with age, ROMA was associated with age and menopausal status (P 〈0.05). Conclusion The serum levels of HE4,CA125 and ROMA index may be a helpful method to assess the risk of epithelioid ovarian cancer.
出处
《中国临床保健杂志》
CAS
2016年第1期58-60,共3页
Chinese Journal of Clinical Healthcare